Retatrutide Ultra-Stack Protocol
Triple-receptor weight-loss stack by Samir Levin. Three orthogonal pathways with no receptor overlap. Phase 2 data: 24.2% average weight loss at 48 weeks. PDF guide — instant email delivery.
Three stacked modules
- Module 1 — Retatrutide: GIP-R + GLP-1R + GcgR (triple incretin receptor agonist). 24.2% weight loss in Phase 2 (OASIS-1 trial).
- Module 2 — Cagrilintide: Amylin-R (CTR + RAMP). Brainstem satiety via area postrema. +7% vs semaglutide alone (CagriSema Phase 3).
- Module 3 — 5-Amino-1MQ: NNMT inhibitor. Adipocyte NAD+/SIRT1 activation. White-to-beige fat conversion. Preclinical: fat loss without caloric restriction.
Titration schedule
- Phase 1: 1 mg/week × 4 weeks (adaptation)
- Phase 2: 2 mg/week × 4 weeks
- Phase 3: 4 mg/week × 4+ weeks
- Phase 4: 8 mg/week × 4+ weeks (primary therapeutic dose)
- Phase 5: 12 mg/week (maximum, for plateau after 8 mg)